Zacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $240,000.00
Wall Street brokerages expect Abeona Therapeutics Inc (NASDAQ:ABEO) to report sales of $240,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Abeona Therapeutics’ earnings, with the lowest sales estimate coming in at $200,000.00 and the highest estimate coming in at $300,000.00. Abeona Therapeutics posted sales of $260,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 7.7%. The company is scheduled to announce its next quarterly earnings results on Friday, March 30th.
On average, analysts expect that Abeona Therapeutics will report full-year sales of $240,000.00 for the current fiscal year, with estimates ranging from $800,000.00 to $900,000.00. For the next financial year, analysts anticipate that the firm will report sales of $1.21 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 23.95% and a negative net margin of 2,439.73%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.22 million.
Shares of Abeona Therapeutics (ABEO) opened at $15.30 on Tuesday. Abeona Therapeutics has a twelve month low of $4.05 and a twelve month high of $22.75.
Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Abeona Therapeutics by 11.2% during the second quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after buying an additional 108,730 shares during the last quarter. State Street Corp acquired a new position in shares of Abeona Therapeutics during the second quarter valued at about $1,900,000. Northern Trust Corp raised its position in shares of Abeona Therapeutics by 406.3% during the second quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after buying an additional 206,775 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Abeona Therapeutics during the third quarter valued at about $3,527,000. Finally, Geode Capital Management LLC raised its position in shares of Abeona Therapeutics by 2.4% during the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares during the last quarter. 41.95% of the stock is owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.